The drug is a joint venture between Bayer Healthcare Pharmaceuticals and Johnson & Johnson. Johnson & Johnson has applied for approval for short-term use of the drug in the prevention of deep-vein thrombosis and pulmonary embolism in patients undergoing total hip and knee replacement surgery.
The company has recently finished clinical trials on the longer-term use of rivaroxaban in patients with acute coronary syndrome.
Read about the FDA panel’s recommendation to approve rivaroxaban.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.